TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02862548
Drug: Other approved antivirals
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
Study: NCT00004938
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01617655
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study: NCT04562558
Drug: Dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25mg/m2 (2mg max dose)intravenous every 14 days.
Study: NCT04568018
Drug: Surfactant
Normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of surfactant emulsion at 150 mg
Study: NCT02621619
Drug: Normal saline + 0.5 mg IV hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
Study: NCT03920878
Drug: Aflibercept injected Pre- and Post-operatively
Normalized name: lidocaine
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
Study: NCT03920878
Drug: Aflibercept injected intraoperatively
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
Study: NCT05382988
Drug: Sodium zirconium cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental group was required to take SZC 10g at 6 am on the day of surgery.
Study: NCT03917225
Drug: MIN-102
Normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
Study: NCT00525239
Drug: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg, twice daily, for four weeks
Study: NCT03058822
Drug: BMS-931699
Normalized name: BMS-931699
DrugBank: Lulizumab pegol (DB15441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-931699 single subcutaneous dose on Day 1
Study: NCT03297216
Drug: 17P
Normalized name: Hydroxyprogesterone caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic progestin
Study: NCT01332604
Drug: GDC-0980
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral escalating dose
Study: NCT01332604
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous repeating dose
Study: NCT00603733
Drug: 5-ASA (5-Aminosalicylate)
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablet (modified extended release)
Study: NCT00603733
Drug: 5-ASA (5-Aminosalicylate)
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablet
Study: NCT00680953
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Study: NCT00680953
Drug: Alendronate sodium hydrate
Normalized name: Alendronate Sodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet once a week for 24 months
Study: NCT03057951
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily
Study: NCT01081821
Drug: multi-dose JNJ-39758979 /matching placebo
DrugBank: JNJ-39758979 (DB18899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
Study: NCT03994393
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.
Study: NCT03994393
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.
Study: NCT02293993
Drug: SGI-110
Normalized name: SGI-1776
DrugBank: SGI-1776 (DB12494)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00387348
Drug: escitalopram oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram oxalate 10 mg once daily for 4 weeks
Study: NCT00838461
Drug: HSD-016
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03027388
Drug: LB-100
Normalized name: LB-100
DrugBank: LB-100 (DB15412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
Study: NCT03342456
Drug: Amoxicillin Capsules
Normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
Study: NCT03342456
Drug: Ilaprazole Enteric-Coated Tablets
Normalized name: lipase
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
Study: NCT03342456
Drug: Furazolidone Tablets
Normalized name: Furazolidone Tablets
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
Study: NCT03342456
Drug: Potassium Citrate Tablets
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
Study: NCT00651612
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
Study: NCT00651612
Drug: Concurrent brimonidine 0.2% and 0.5% timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
Study: NCT00382213
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00830115
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
Study: NCT00505752
Drug: AS900672-Enriched 50 microgram (mcg)
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study: NCT00505752
Drug: AS900672-Enriched 100 mcg
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
Study: NCT00505752
Drug: AS900672-Enriched 150 mcg
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
Study: NCT00505752
Drug: Follitropin alfa 150 international unit (IU)
Normalized name: follitropin alfa 75 UNT
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study: NCT00505752
Drug: Recombinant human chorionic gonadotropin (r-hCG)
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
Study: NCT00292747
Drug: Drotaverine
Normalized name: drotaverine
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00292747
Drug: Drotaverine Placebo
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00232505
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02468206
Drug: N-butyl-2-cyanoacrylate
Normalized name: N-butyl-2-cyanoacrylate
DrugBank: Enbucrilate (DB12358)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00502528
Drug: BQ-123
Normalized name: BQ-123
DrugBank: BQ-123 (DB12054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-interventional
Study: NCT01766219
Drug: 6,8-bis(benzylthio)octanoic acid
Normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02591888
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
Study: NCT02778945
Drug: Rocuronium 0.9 mg/kg
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
Study: NCT02778945
Drug: Rocuronium 0.6 mg/kg
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
Study: NCT00422123
Drug: Quetiapine fumarate (Seroquel) SR
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02169804
Drug: Androxal 25 mg
Normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04238884
Drug: Voriconazole preemptive genotyping strategy
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
Study: NCT04238884
Drug: Voriconazole clinical practice
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
Study: NCT02310906
Drug: SRP-4053
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP-4053 (golodirsen) solution for IV infusion.
Study: NCT01902862
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
Study: NCT01902862
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
Study: NCT01108562
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
Study: NCT02197897
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-center, two-stage phase-II clinical trial (Simon design)
Study: NCT01917708
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
Study: NCT01371448
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02384395
Drug: Dolutegravir 50 mg
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial therapy for AHI
Study: NCT02384395
Drug: Lamivudine 300 mg
Normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial therapy for AHI
Study: NCT02384395
Drug: Abacavir 600 mg
Normalized name: abacavir 600 MG
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial therapy for AHI
Study: NCT03600493
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
Study: NCT03600493
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
Study: NCT06177119
Drug: Metronidazole during SRP
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
Study: NCT06177119
Drug: Amoxicillin during SRP
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
Study: NCT06177119
Drug: Metronidazole after SRP
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
Study: NCT06177119
Drug: Amoxicillin after SRP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
Study: NCT02119026
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7,5 mg/kg given on d1 q3w
Study: NCT02119026
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 iv. d 1 q3w
Study: NCT02119026
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 iv. d 1 q3w .
Study: NCT02084069
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005812
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02402712
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
Study: NCT02402712
Drug: pertuzumab [Perjeta]
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
Study: NCT02016898
Drug: Mitomycin-C
Normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01877590
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02453009
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT02453009
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02453009
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form : soft gelatin capsules Route of administration: oral
Study: NCT03017846
Drug: Cantharidin
Normalized name: cantharidin
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of topical cantharidin
Study: NCT01524237
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT02471911
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Rituximab 375 mg/m2 on D1
Study: NCT02471911
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Etoposide 100 mg/m2 on D1-3
Study: NCT02471911
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Carboplatin AUC 5 on D2
Study: NCT02471911
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ifosfamide 5 g/m2 on D2
Study: NCT02471911
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
Study: NCT00228930
Drug: Tamoxifen (pharmacodynamic analysis)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20mg po daily
Study: NCT00992186
Drug: Carlumab
Normalized name: Carlumab
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
Study: NCT00988260
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
Study: NCT00988260
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
Study: NCT00988260
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
Study: NCT02451202
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02451202
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00863980
Drug: Micardis (Telmisartan)
Normalized name: telmisartan Oral Tablet [Micardis]
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-80 mg/day oral administration
Study: NCT00863980
Drug: Blopress (Candesartan)
Normalized name: BANDAGE,STRETCH,LOPRESS 2.3IN X 5.4YD
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8-12 mg/day oral administration
Study: NCT00516412
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT01824264
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active comparator treatment dose